The Wistar Institute

The United States of America As Represented by the Department of Health

Klara Berencsi

Eva Gonczol

Robert F Rando

Stanley A Plotkin

Robert P Ricciardi

Ewa Gonczol

Csaba Kari

Novel DNA molecules for in vitro and in vivo expression of HCMV gB, gB transmembrane deleted derivatives, pp65, pp150, and IE-exon-4 proteins are described. Preferably, the molecules are plasmids. Also described are methods of using these DNA molecules to induce immune responses to HCMV, and the use of a plasmid of the invention to prime immune responses to HCMV vaccines.

Human cytomegalovirus DNA constructs and uses therefor

A method for preventing or retarding the development atherosclerotic lesions or restenosis involves administering to a subject, preferably a human, an effective amount of an anti-viral composition directed against CMV, and optionally an anti-microbial composition directed against,. These compositions may be conventional chemical anti-microbial pharmaceutics. Alternatively, the compositions may contain a cytomegalovirus (CMV) protein or fragment thereof (or nucleic acid containing compositions expressing such protein or fragment). Such compositions may contain an immunogenic,protein or fragment thereof (or nucleic acid containing compositions expressing such protein or fragment). The protein/nucleic acid compositions are administered in an amount capable of inducing cell mediated immunity and/or antibody response in the subject.

Methods and compositions for retarding the development of atherosclerotic lesions

The present invention provides a non-defective adenovirus recombinant expression system for the expression of the HCMV gB subunit, an immunogenic fragment of the gB subunit, and for the expression of non-structural immediate-early exon 4 proteins, said recombinant HCMV-expressing adenovirus being useful as a vaccine.

Recombinant cytomegalovirus vaccine

Growing community of inventors

Rosemont, PA, United States of America

Klara Berencsi